The Dispersome® platform technology The Dispersome® technology uses high quality whey protein isolate (WPI), an environmentally friendly by-product from cheese production, to disrupt the drug crystal structure. A unique amorphous composition is formed from the mixture of WPI and drug molecules resulting in improved drug solubility and bioavailability. The technology enables lowering of the drug dose, resulting in fewer and smaller tablets enhancing patient compliance as well as minimizing any side effects. Dispersomes® can be produced using standard pharmaceutical equipment.
ZERION receives a DKK 1.9 million grant from the Danish Innovation Fund
(Copenhagen, October 1, 2020). The Danish Innovation Fund has awarded the drug delivery company ZERION a grant of DKK 1.9 million under its InnoBooster program. The grant will advance the development of ZERION’s Dispersome® drug formulations . The InnoBooster grant covers about one third of the total project costs
“We are extremely grateful to receive this support from the Innovation Fund. This is the 3rd grant we have obtained from the Innovation Fund and their support has been instrumental in building ZERION as a company”, says Ole Wiborg, CEO of ZERION.
ZERION has previously (2019) received a smaller InnoBooster project grant as well as two highly competitive InnoFounder grants supporting its founder team.
Poor drug solubility is a major problem for the pharma industry
ZERION is a pharmaceutical development company specialised in improving the bioavailability of oral drug products by increasing their solubility. The company has pioneered the patented Dispersome® formulation technology that enables poorly soluble drugs to reach their true therapeutic potential. Poor drug solubility is one of the biggest challenges hampering the commercial development of novel small molecule drugs. Approximately 90% of all oral drugs in pharmaceutical pipelines do not sufficiently dissolve in the gastrointestinal tract and therefore cannot be absorbed into the circulation and exert their therapeutic effect. Many otherwise promising drug candidates are thus discontinued during early-stage development due to poor bioavailability.
The Dispersome® platform technology The Dispersome® technology uses high quality whey protein isolate (WPI), an environmentally friendly by-product from cheese production, to disrupt the drug crystal structure. A unique amorphous composition is formed from the mixture of WPI and drug molecules resulting in improved drug solubility and bioavailability. The technology enables lowering of the drug dose, resulting in fewer and smaller tablets enhancing patient compliance as well as minimising any side effects. Dispersomes® can be produced using standard pharmaceutical equipment.
In addition to its internal product portfolio, ZERION is also collaborating with established pharmaceutical companies to assist them in optimising the therapeutic performance of their drug compounds.
Spinout from University of Copenhagen
ZERION was formed in 2019 as a spinout from the University of Copenhagen and has already established itself as a leading player in the field of drug solubility enhancing technology. The company’s outstanding team includes seasoned biotech entrepreneurs, world leading experts in drug delivery technologies, and specialists in key areas of pharmaceutical development and manufacturing.
The InnoBooster program
Innovation Fund Denmark aims to help promising ideas be converted into growth and employment in Denmark. InnoBooster is Innovation Fund Denmark’s program for knowledge-based innovation projects in small and medium- sized businesses and entrepreneurships.
The InnoFounder program
InnoFounder is a program for founders with an innovative business idea in its early phase. There must be a significant amount of development of the idea and its commercialisation outstanding. For more information on the programs, visit https://innovationsfonden.dk/en/about-innovation-fund-denmark
For more information, please visit www.zerion.eu or contact
Ole Wiborg, CEO at +45 40 96 80 18
January 10, 2022 (COPENHAGEN, Denmark). The Danish drug development company, Zerion Pharma A/S (ZERION) has completed a new animal study (in dogs) that clearly demonstrates the potential of its patented Dispersome®
(Copenhagen, December 21, 2021). ZERION Pharma A/S, a Danish pharmaceutical company, elected Dr. Dorte Arnbjerg to join its board of directors at an extraordinary general meeting held on December 14, 2021.